New Drug May Reverse Serious Bleeding Effects of Xarelto, Portola Says

Published on January 13, 2015 by Sandy Liebhard

Text-Size:A A A+

 

An experimental drug from Portola Pharmaceuticals Inc. may effectively reverse the effects of a blood thinner named in Xarelto lawsuit claims, according to Reuters.com.

Results of the study were released on January 9th and examine the reported benefits of andexanet alfa, a drug shown to stop internal bleeding episodes sustained by users aged between 50 and 75 years. Further data is expected to be released in mid-2015, the company said that day.

The Reuters report indicates that Portola said in October 2014 that andexanet alfa was proven to reverse the effects of Eliquis, an anti-clotting medication from Bristol-Myers Squibb and Pfizer that belongs to the same class as Xarelto. Andexanet alfa received FDA clearance in 2013, and was designed to reverse the anti-clotting action of similar medications.

According to Portola, whose shares went up 11 percent in premarket trading the day its study was released, major Eliquis and Xarelto internal bleeding episodes occur in 1 to 4 percent of patients, who may also require emergency surgery.

Xarelto Lawsuits Accuse J&J, Bayer of Failing to Warn that Internal Bleeding Injuries are Irreversible

Xarelto is a blood-thinning medication that was approved in 2011 to treat patients with atrial fibrillation, and to reduce the risk of stroke and heart attack in individuals with serious cardiovascular problems. The drug is also cleared by the U.S. Food and Drug Administration (FDA) to treat deep vein thrombosis and pulmonary embolism.  In December 2014, similar lawsuits against the makers of this medication were centralized in the U.S. District Court, Eastern District of Louisiana, where a federal multidistrict litigation (MDL) is now underway. Xarelto lawsuits accuse the Johnson & Johnson subsidiary, Janssen, and Bayer Healthcare of failing to properly warn about side effects that were allegedly caused by its product, which belongs to a class of new-generation blood thinners that also includes Eliquis.

Since its entrance into the U.S. market, Johnson & Johnson’s Janssen unit and Bayer have touted Xarelto’s convenience over warfarin, a similar product that has been used for generations. What they fail to note, however, is that internal bleeding injuries caused by this medication can be stopped via the administration of Vitamin K, while there is no reversal agent for Xarelto bleeding. Plaintiffs point to this in their internal bleeding lawsuits, court documents indicate.

Consider a Xarelto Lawsuit

Call a Xarelto lawyer today for more information about claims involving this medication. Contact an attorney today at .

Web Analytics